A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Our clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which we completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (“RA”), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (“CeD”) and eosinophilic esophagitis (“EoE”), and ANB101, a BDCA2 modulator, in a Phase 1a trial. We also discovered and out-licensed, in financial collaborations, multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli (dostarlimab-gxly) or “Jemperli”) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals Inc. (“Vanda”). We currently recognize revenue from milestones and royalties achieved under our immuno-oncology collaboration with GSK and license and transition services revenue from our collaboration with Vanda.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 235M | 235M | 91M | - | - | 63M |
| Net Income | -13M | -13M | -145M | -164M | -129M | -58M |
| EPS | $-0.46 | $-0.46 | $-5.12 | $-6.08 | $-4.57 | $-2.11 |
| Free Cash Flow | 20M | 20M | -136M | -122M | -74M | -47M |
| ROIC | 10.4% | 88.6% | -18.8% | -185.7% | -49.1% | -16.2% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.38 | 0.38 | 0.23 | 4.13 | 1.33 | 0.80 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 48M | 48M | -115M | -164M | -115M | -57M |
| Operating Margin | 20.4% | 20.4% | -125.9% | - | - | -89.9% |
| ROE | -35.6% | -24.5% | -204.9% | -185.7% | -49.1% | -16.2% |
| Shares Outstanding | 29M | 29M | 28M | 27M | 28M | 27M |
ANAPTYSBIO, INC passes 2 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 100.8x vs a median of 73.5x. Total shareholder yield (buybacks) is 3.5%.
ANAPTYSBIO, INC (ANAB) has a 5-year average return on invested capital (ROIC) of -36.2%. This is below average and may indicate limited pricing power.
ANAPTYSBIO, INC (ANAB) has a market capitalization of $2.0B. It is classified as a small-cap stock.
ANAPTYSBIO, INC (ANAB) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 3.47%.
ANAPTYSBIO, INC (ANAB) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ANAPTYSBIO, INC (ANAB) reported annual revenue of $235 million in its most recent fiscal year, based on SEC EDGAR filings.
ANAPTYSBIO, INC (ANAB) has a net profit margin of -5.6%. The company is currently unprofitable.
ANAPTYSBIO, INC (ANAB) generated $20 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
ANAPTYSBIO, INC (ANAB) has a debt-to-equity ratio of 0.38. This indicates a conservatively financed balance sheet.
ANAPTYSBIO, INC (ANAB) reported earnings per share (EPS) of $-0.46 in its most recent fiscal year.
ANAPTYSBIO, INC (ANAB) has a return on equity (ROE) of -24.5%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 11 years of financial data for ANAPTYSBIO, INC (ANAB), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ANAPTYSBIO, INC (ANAB) has a book value per share of $1.29, based on its most recent annual SEC filing.